DTx Neuroglee raises $10 million to treat neurodegenerative diseases

DTx Neuroglee raises $10 million to treat neurodegenerative diseases

Posted Sep 11, 2021 from

A Boston-based startup is looking to help treat neurodegenerative disease with a smartphone-based digital therapeutic called Neuroglee.

This morning the startup got a boost when it closed a $10 million Series A round led by Openspace Ventures with participation from EDBI, Eisai Co and individual investors. 

“Various techniques have been demonstrated to slow or improve cognitive impairment in Alzheimer’s disease,” Aniket Singh Rajput, CEO of Neuroglee, told MobiHealthNews in an email.

“While the majority of this work has been demonstrated in the hospital setting in inpatient programs, we had a dream of bringing that type of therapy to patients in their own homes – especially to those patients who aren’t near a clinical center of excellence with this type of program.

"We will now be able to do that by working with patients’ clinicians across the country via our virtual care and digital therapy solutions.”


See Topics

See Also

Next Article